News
Keep up to date with our recent breakthroughs and partnerships as we develop novel life changing therapeutics for a range of inflammatory and fibrotic diseases.
Latest updates
Calluna Pharma Announces U.S. FDA Orphan Drug Designation Granted to CAL101 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Oslo, Norway and Boston, USA, 31 October 2025: Calluna Pharma AS, a clinical stage biotechnology company pioneering first-in-class antibodies to treat...
Read more
Calluna Pharma Announces Initiation of Phase 2 AURORA Study of CAL101 for Idiopathic Pulmonary Fibrosis
Oslo, Norway and Boston, Massachusetts, 26 August 2025: Calluna Pharma AS, a clinical stage biotechnology company pioneering first-in-class antibodies to treat...
Read more
Calluna Announces Three Poster Presentations at the 2025 American Thoracic Society International Conference
Oslo, Norway and Boston, MA, 29 April 2025: Calluna Pharma AS (Calluna), a clinical stage biotechnology company pioneering first-in-class antibodies to...
Read more
Calluna Pharma successfully completes Phase 1 clinical study of CAL101, a first-in-class therapeutic for fibrotic and fibro-inflammatory indications
Oslo, Norway, 23 October 2024: Calluna Pharma AS (Calluna), a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory...
Read more
Calluna Pharma appoints Mark Gaffney as Chief Executive Officer and Mark Altmeyer as Independent Chair of the Board
Executive appointments will drive growth strategy and progression of clinical pipeline Oslo, Norway and Boston, MA, 9 October 2024: Calluna...
Read more
Calluna Pharma appoints Margrethe Sørgaard as Senior Vice President of Clinical Operations and Pharmacovigilance
First senior executive appointment made following Company launch to oversee strategic development of clinical programs
Read more
Calluna Pharma launches and announces EUR 75 million Series A financing to develop novel therapies for inflammatory and fibrotic diseases
Oxitope Pharma (Oxitope) and Arxx Therapeutics (Arxx) announced their merger to form Calluna Pharma Inc.
Read moreDownload Our Investor Presentation
Download presentation
"*" indicates required fields
